The IMP p62 was originally identified as a tumor-associated autoantigen with autoantibodies against p62 detected in HCC patients4 and in several other types of cancer.24, 25 Interestingly, despite several investigations of p62 autoantibodies as a potential tumor marker and a recently suggested resistance of IMP2 knockout mice toward malignancy,26 functional implications of the p62 protein in carcinogenesis are widely unknown. This evidence concerns the gene IGF2BP2 and hepatocellular carcinoma.